Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

Three educational and discussion events with 35 key specialists from federal and regional cancer centers representing 7 federal districts were organized by Pfizer with the support of TS Oncology. The events were organized on the basis of the "OncoForum" platform (virtual platform developed...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Board Editorial
Formato:	article
Lenguaje:	RU
Publicado:	IP Habib O.N. 2021
Materias:	hr+/her2-negative metastatic breast cancer cdk4/6 inhibitors palbociclib brca1/2-mutated her2-negative metastatic breast cancer parp inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fdf7a1125c7e47ddb5d238c15ee4320e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fdf7a1125c7e47ddb5d238c15ee4320e
record_format	dspace
spelling	oai:doaj.org-article:fdf7a1125c7e47ddb5d238c15ee4320e2021-11-30T16:55:01ZPlace of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer1815-14341815-144210.26442/18151434.2021.3.201122https://doaj.org/article/fdf7a1125c7e47ddb5d238c15ee4320e2021-11-01T00:00:00Zhttps://modernonco.orscience.ru/1815-1434/article/viewFile/88139/66283https://doaj.org/toc/1815-1434https://doaj.org/toc/1815-1442Three educational and discussion events with 35 key specialists from federal and regional cancer centers representing 7 federal districts were organized by Pfizer with the support of TS Oncology. The events were organized on the basis of the "OncoForum" platform (virtual platform developed and operated by TS Oncology). Experts shared their opinion on CDK4/6 inhibitors and PARP inhibitors place in the optimal therapy strategy for patients with HR+/HER2- metastatic breast cancer (mBC) and BRCA-associated HER2- mBC in Russia. This review presents results of the discussions on practical aspects of defining the optimal profiles of patients with HR+/HER2- mBC and BRCA-associated HER2- mBC for using CDK4/6 inhibitors and PARP inhibitors, evaluating the efficacy data and toxicity profiles for each of the CDK4/6 inhibitors and PARP inhibitors, as well as market access specifities for CDK4/6 inhibitors to patients with HR+/HER2- mBC and PARP inhibitors to patients with gBRCA-associated HER2- mBC in different regions of the Russian Federation.Board EditorialIP Habib O.N.articlehr+/her2-negative metastatic breast cancercdk4/6 inhibitorspalbociclibbrca1/2-mutated her2-negative metastatic breast cancerparp inhibitorstalazoparibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282RUСовременная онкология, Vol 23, Iss 3, Pp 470-476 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	hr+/her2-negative metastatic breast cancer cdk4/6 inhibitors palbociclib brca1/2-mutated her2-negative metastatic breast cancer parp inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	hr+/her2-negative metastatic breast cancer cdk4/6 inhibitors palbociclib brca1/2-mutated her2-negative metastatic breast cancer parp inhibitors talazoparib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Board Editorial Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
description	Three educational and discussion events with 35 key specialists from federal and regional cancer centers representing 7 federal districts were organized by Pfizer with the support of TS Oncology. The events were organized on the basis of the "OncoForum" platform (virtual platform developed and operated by TS Oncology). Experts shared their opinion on CDK4/6 inhibitors and PARP inhibitors place in the optimal therapy strategy for patients with HR+/HER2- metastatic breast cancer (mBC) and BRCA-associated HER2- mBC in Russia. This review presents results of the discussions on practical aspects of defining the optimal profiles of patients with HR+/HER2- mBC and BRCA-associated HER2- mBC for using CDK4/6 inhibitors and PARP inhibitors, evaluating the efficacy data and toxicity profiles for each of the CDK4/6 inhibitors and PARP inhibitors, as well as market access specifities for CDK4/6 inhibitors to patients with HR+/HER2- mBC and PARP inhibitors to patients with gBRCA-associated HER2- mBC in different regions of the Russian Federation.
format	article
author	Board Editorial
author_facet	Board Editorial
author_sort	Board Editorial
title	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
title_short	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
title_full	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
title_fullStr	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
title_full_unstemmed	Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
title_sort	place of cdk 4/6 and parp inhibitors in the modern treatment approach of her2-negative breast cancer
publisher	IP Habib O.N.
publishDate	2021
url	https://doaj.org/article/fdf7a1125c7e47ddb5d238c15ee4320e
work_keys_str_mv	AT boardeditorial placeofcdk46andparpinhibitorsinthemoderntreatmentapproachofher2negativebreastcancer
_version_	1718406481486807040

Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer

Ejemplares similares